Walleye Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20.6M | Buy |
2,300,628
+2,145,936
| +1,387% | +$19.2M | 0.08% | 127 |
|
|
2025
Q1 | $1.16M | Sell |
154,692
-204,830
| -57% | -$1.54M | 0.01% | 791 |
|
|
2024
Q4 | $2.7M | Buy |
359,522
+100,140
| +39% | +$753K | 0.01% | 597 |
|
|
2024
Q3 | $1.97M | Buy |
259,382
+50,557
| +24% | +$384K | ﹤0.01% | 769 |
|
|
2024
Q2 | $1.29M | Buy |
208,825
+145,073
| +228% | +$897K | ﹤0.01% | 1002 |
|
|
2024
Q1 | $324K | Sell |
63,752
-650,706
| -91% | -$3.31M | ﹤0.01% | 1602 |
|
|
2023
Q4 | $4.28M | Buy |
714,458
+3,807
| +0.5% | +$22.8K | 0.01% | 402 |
|
|
2023
Q3 | $5.03M | Buy |
710,651
+534,472
| +303% | +$3.78M | 0.01% | 389 |
|
|
2023
Q2 | $1.24M | Buy |
176,179
+166,635
| +1,746% | +$1.17M | ﹤0.01% | 673 |
|
|
2023
Q1 | $79.6K | Sell |
9,544
-595,989
| -98% | -$4.97M | ﹤0.01% | 1544 |
|
|
2022
Q4 | $6.95M | Buy |
605,533
+364,119
| +151% | +$4.18M | 0.13% | 191 |
|
|
2022
Q3 | $3.04M | Buy |
241,414
+181,816
| +305% | +$2.29M | 0.06% | 318 |
|
|
2022
Q2 | $631K | Sell |
59,598
-122,969
| -67% | -$1.3M | 0.02% | 883 |
|
|
2022
Q1 | $2.97M | Buy |
+182,567
| New | +$2.97M | 0.08% | 244 |
|
|
2021
Q4 | – | Sell |
-41,131
| Closed | -$591 | – | 2037 |
|
|
2021
Q3 | $591 | Buy |
41,131
+27,173
| +195% | +$390 | 0.02% | 695 |
|
|
2021
Q2 | $221 | Buy |
+13,958
| New | +$221 | 0.01% | 1015 |
|
|
2020
Q2 | – | Sell |
-156,507
| Closed | -$313K | – | 603 |
|
|
2020
Q1 | $313K | Buy |
156,507
+53,157
| +51% | +$106K | 0.07% | 226 |
|
|
2019
Q4 | $357K | Buy |
+103,350
| New | +$357K | 0.02% | 255 |
|